The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Depressive Signs and Symptoms in Schizophrenia: A Prospective Blinded Trial of Olanzapine and Haloperidol
Abstract
BACKGROUND: Depressive signs and symptoms during the course of schizophrenia are common and have been associated with impaired recovery and a higher risk of self-harm. Novel antipsychotic agents introduce new pharmacological avenues that may differentially affect schizophrenic signs and symptoms, including depression. METHODS: This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d). Patients were evaluated with the Positive and Negative Syndrome Scale, the Montgomery-Asberg Depression Rating Scale, and the Simpson-Angus Rating Scale. The trial consisted of a 6-week and a 46-week masked responder maintenance period. RESULTS: At least moderate depressive signs and symptoms (Montgomery-Asberg Depression Rating Scale score, > or =16) were seen in slightly more than half of this sample. Although both treatments were associated with short-term baseline-to-end point improvement on the Montgomery-Asberg Depression Rating Scale, olanzapine-associated improvements were significantly superior to those observed with haloperidol (P=.001). Furthermore, the response rate for the group receiving olanzapine (> or =50% improvement on the Montgomery-Asberg Depression Rating Scale after at least 3 weeks of treatment) was also significantly higher (P=.008). Analysis demonstrated that improvement in positive, negative, and/or extrapyramidal symptoms was associated with mood improvement (indirect effect); however, most of the olanzapine treatment effect on mood was a primary direct effect (57%) that alone was significantly greater than that seen with haloperidol treatment (P<.001). CONCLUSIONS: Depressive signs and symptoms in schizophrenia are responsive to treatment. The pleotrophic pharmacological features of olanzapine, through 1 or more non-D2-mediated pathways, likely contribute to its superior treatment effect. Better control of the mood disorders accompanying schizophrenia holds the possibility for improved patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,326
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised
Kobylski, T. P. (1988) · Psychosomatics · doi:10.1016/s0033-3182(88)72438-x · Cited by 1,054
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms
Andreasen, N. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950170015003 · Cited by 734
'Akinetic Depression' in Schizophrenia
Van Putten, T. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770330075006 · Cited by 386
Birchwood, M., Mason, R., MacMillan, F., & Healy, J. (1993) · Psychological Medicine · doi:10.1017/s0033291700028488 · Cited by 354
Depression in first-episode schizophrenia
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1643 · Cited by 316
Akinesia: A Poorly Recognized Drug-Induced Extrapyramidal Behavioral Disorder
Rifkin, A. (1975) · Archives of General Psychiatry · doi:10.1001/archpsyc.1975.01760230138011 · Cited by 258
Sax, K. W., Strakowski, S. M., Keck, P. E., Upadhyaya, V. H., West, S. A., & McElroy, S. L. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.1.68 · Cited by 232
Diagnosis of Secondary Depression in Schizophrenia: Implications for DSM-IV
Siris, S. G. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.1.75 · Cited by 217
Platelet serotonin-2 receptor binding sites in depression and suicide
Pandey, G. N., Pandey, S. C., Janicak, P. G., Marks, R. C., & Davis, J. M. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90576-n · Cited by 212
What Do Depression Rating Scales Measure?
Snaith, P. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.163.3.293 · Cited by 168
Prospects for pharmacotherapy of schizophrenia
Pickar, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90469-7 · Cited by 167
The Nature and Prevalence of Depression in Chronic Schizophrenic In-patients
Barnes, T. R. E., Curson, D. A., Liddle, P. F., & Patel, M. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.4.486 · Cited by 166
Adjunctive Imipramine in the Treatment of Postpsychotic Depression
Siris, S. G. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180043008 · Cited by 149
Nefazodone: A Review of its Pharmacology and Clinical Efficacy in the Management of Major Depression
Davis, R., Whittington, R., & Bryson, H. M. (1997) · Drugs · doi:10.2165/00003495-199753040-00006 · Cited by 142
Depression, Parkinsonian Symptoms, and Negative Symptoms in Schizophrenics Treated With Neuroleptics
Prosser, E. S., Csernansky, J. G., Kaplan, J., Thiemann, S., BECKER, T. J., & Hollister, L. E. (1987) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198702000-00006 · Cited by 136
An investigation of the postpsychotic depressive syndrome
McGlashan, T. H., & Carpenter, W. T. (1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.1.14 · Cited by 135
Clinically Significant Drug Interactions with New Immunosuppressive Agents
Mignat, C. (1997) · Drug Safety · doi:10.2165/00002018-199716040-00004 · Cited by 133
Treatment of Secondary Depression in Schizophrenia
Prusoff, B. A. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780050079010 · Cited by 130
Depression in Schizophrenia: Are Neuroleptics, Akinesia, or Anhedonia Involved?
Harrow, M., Yonan, C. A., Sands, J. R., & Marengo, J. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.2.327 · Cited by 129
Bermanzohn, P. C., & Siris, S. G. (1992) · Comprehensive Psychiatry · doi:10.1016/0010-440x(92)90045-r · Cited by 118
Are Prophylactic Antiparkinson Drugs Necessary?
Rifkin, A. E. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280093010 · Cited by 111
The Significance of Depression in the Prediction of Relapse in Chronic Schizophrenia
Johnson, D. A. W. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.152.3.320 · Cited by 109
The Dysphoric Syndrome in Schizophrenia and its Implications for Relapse
Hirsch, S. R., & Jolley, A. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000295986 · Cited by 101
The Composition of the Negative Syndrome of Chronic Schizophrenia
Kibel, D., Laffont, I., & Liddle, P. F. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.162.6.744 · Cited by 98
Frequency and differential diagnosis of depressive syndromes in schizophrenia.
Martin, R. L., Cloninger, C. R., Guzé, S. B., & Clayton, P. J. (1985) · PubMed · Cited by 97
Coadministration of Nefazodone and Benzodiazepines
Barbhaiya, R. H., Shukla, U., Kroboth, P. D., & Greene, D. S. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00003 · Cited by 96
Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors
Lane, R. M. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199612005-00005 · Cited by 95
Depression in Chronic Schizophrenia
AGER, H., & MILSTEIN, L. N. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.7.870-c · Cited by 92
Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty, G. E. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950130029004 · Cited by 83
Knights, A., Okasha, M. S., Salih, M. A., & Hirsch, S. R. (1979) · The British Journal of Psychiatry · doi:10.1192/bjp.135.6.515 · Cited by 79
Depressive States Occurring During the Neuroleptic Treatment of Schizophrenia
Möller, H. ‐., & Zerssen, D. V. (1982) · Schizophrenia Bulletin · doi:10.1093/schbul/8.1.109 · Cited by 69
Depressive and negative symptoms in major psychiatric disorders
Kitamura, T., & Suga, R. (1991) · Comprehensive Psychiatry · doi:10.1016/0010-440x(91)90074-m · Cited by 68
Depressive symptoms in acute schizophrenia
Montgomery, S. (1979) · Progress in Neuro-Psychopharmacology · doi:10.1016/0364-7722(79)90058-4 · Cited by 65
Structural validity of MADRS during antidepressant treatment
Galinowski, A., & Lehert, P. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199510030-00004 · Cited by 65
5.4. Brief Psychiatric Rating Scale (BPRS)
(1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb10905.x · Cited by 60
Depression and Social Adjustment Among Chronic Schizophrenic Outpatients
Glazer, W. M., Prusoff, B. A., John, K., & WILLIAMS, D. (1981) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198111000-00005 · Cited by 59
The clinical course of depressive symptoms in schizophrenia
Leff, J., Tress, K., & Edwards, B. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90036-9 · Cited by 59
Akinesia and postpsychotic depression: a difficult differential diagnosis.
Sg, S. (1987) · PubMed · Cited by 57
Psychotic unipolar depression at follow-up: factors related to psychosis in the affective disorders
Sands, J. R., & Harrow, M. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.995 · Cited by 48
Serotonin, dopamine and their interactions in schizophrenia
Kahn, R. S., & Davidson, M. (1993) · Psychopharmacology · doi:10.1007/bf02245002 · Cited by 41
Depressive syndromes in schizophrenic patients after discharge from hospital
Bandelow, B., Müller, P., Gäebel, W., Köpcke, W., Linden, M., Müller-Spahn, F., Pietzcker, A., Reischies, F. M., Tegeler, J., & ANI Study Group Berlin, D. (1990) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02189981 · Cited by 40
Relationship between depressive and positive symptoms in schizophrenia
Dollfus, S., Petit, M., & Ménard, J.-F. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90078-x · Cited by 36
Apparent Interaction between Nefazodone and Cyclosporine
Helms-Smith, K. M., Curtis, S. L., & Hatton, R. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-5-199609010-00026 · Cited by 35
Depressions in schizophrenia: Some observations on prevalence, etiology, and treatment
Johnson, D. A. W. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb02466.x · Cited by 32
Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo.
Preskorn, S. H., Alderman, J., Greenblatt, D. J., & Wd, H. (1997) · PubMed · Cited by 29
Distinguishing Depressive and Negative Symptoms in Chronic Schizophrenia
Whiteford, H., Riney, S. J., & Csernansky, J. G. (2010) · Psychopathology · doi:10.1159/000284506 · Cited by 28
Depression in first-episode schizophrenia
Koreen, A. R. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90392-d · Cited by 20
Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression
Siris, S. G., Strahan, A., Mandeli, J., Casey, E., & Cooper, T. B. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90037-0 · Cited by 19
Cited by
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationOlanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Self-citationDepression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents
Siris, S. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1379 · Cited by 427
Metadata
- Authors
- Tollefson, G. D., Sanger, T. M., Lu, Y., & Thieme, M. E.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1998-03-01
- Volume
- 55
- Issue
- 3
- Pages
- 250
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2024129324
- Cited by
- 261
- References
- 57
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.